---
---

# 42 U.S.C., USLM ref /us/usc/t42/s300cc–14

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schXXI/ptB/m__us_usc_t42_s300cc–13.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schXXI/ptB/m__us_usc_t42_s300cc–15.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300cc%E2%80%9314)

## § 300cc–14. Evaluation of certain treatments

    (a) __Establishment of program__ 

        (1)

         After consultation with the AIDS Research Advisory Committee established pursuant to [section 300cc–3 of this title][/us/usc/t42/s300cc–3], the Secretary shall establish a program for the evaluation of drugs that—

            (A) are not approved by the Commissioner of Food and Drugs for the purpose of treatments with respect to acquired immune deficiency syndrome; and

            (B) are being utilized for such purpose by individuals infected with the etiologic agent for such syndrome.

        (2) The program established under paragraph (1) shall include evaluations of the effectiveness and the risks of the treatment involved, including the risks of foregoing treatments with respect to acquired immune deficiency syndrome that are approved by the Commissioner of Food and Drugs.

    (b) __Authority with respect to grants and contracts__ 

        (1) For the purpose of conducting evaluations required in subsection (a) of this section, the Secretary may make grants to, and enter into cooperative agreements and contracts with, public and nonprofit private entities.

        (2)

         Nonprofit private entities under paragraph (1) may include nonprofit private organizations that—

            (A) are established for the purpose of evaluating treatments with respect to acquired immune deficiency syndrome; and

            (B) consist primarily of individuals infected with the etiologic agent for such syndrome.

    (c) __Scientific and ethical guidelines__ 

        (1) The Secretary shall establish appropriate scientific and ethical guidelines for the conduct of evaluations carried out pursuant to this section. The Secretary may not provide financial assistance under subsection (b)(1) of this section unless the applicant for such assistance agrees to comply with such guidelines.

        (2)

         The Secretary may establish the guidelines described in paragraph (1) only after consulting with—

            (A) physicians whose clinical practice includes a significant number of individuals with acquired immune deficiency syndrome;

            (B) individuals who are infected with the etiologic agent for such syndrome; and

            (C) other individuals with appropriate expertise or experience.

    (d) __Authorization of appropriations__ 

        For the purpose of carrying out this section, there are authorized to be appropriated such sums as may be necessary.

([July 1, 1944, ch. 373][/us/act/1944-07-01/ch373], title XXIII, § 2314, as added [Pub. L. 100–607, title II, § 201(4)][/us/pl/100/607/s201/4], Nov. 4, 1988, [102 Stat. 3069][/us/stat/102/3069]; amended [Pub. L. 103–43, title XX, § 2008(d)(3)][/us/pl/103/43/s2008/d/3], June 10, 1993, [107 Stat. 212][/us/stat/107/212].)

 __Prior Provisions__ 

    A prior section 300cc–14, act July 1, 1944, § 2315, was successively renumbered by subsequent acts and transferred, see section 238l of this title.

 __Amendments__ 

    1993—Subsec. (a)(1). [Pub. L. 103–43][/us/pl/103/43] substituted “AIDS Research Advisory Committee” for “Clinical Research Review Committee” in introductory provisions.

----------

[Previous](./../../../../../..//us/usc/t42/ch6A/schXXI/ptB/m__us_usc_t42_s300cc–13.md) | [Next](./../../../../../..//us/usc/t42/ch6A/schXXI/ptB/m__us_usc_t42_s300cc–15.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300cc%E2%80%9314)

----------
----------

[/us/usc/t42/s300cc–3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft42%2Fs300cc%E2%80%933
[/us/act/1944-07-01/ch373]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fact%2F1944-07-01%2Fch373
[/us/pl/100/607/s201/4]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F100%2F607%2Fs201%2F4
[/us/stat/102/3069]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F102%2F3069
[/us/pl/103/43/s2008/d/3]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F103%2F43%2Fs2008%2Fd%2F3
[/us/stat/107/212]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F107%2F212
[/us/pl/103/43]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F103%2F43


